(Removes incorrect reference to a kidney disease treatment deal from the headline)
Feb 18 (Reuters) – Australia’s CSL said on Wednesday it had entered into an exclusive licensing agreement with Eli Lilly and Co, granting it certain rights to develop and commercialise clazakizumab, an antibody aimed at preventing heart-related illness and death in people with end‑stage kidney disease.
(Reporting by Shivangi Lahiri in Bengaluru; Editing by Maju Samuel)
Comments